Local and systemic toxicity of h-R3, an anti-epidermal growth factor receptor monoclonal antibody, labeled with 188osmiun after the intracerebral administration in rats

Experimental and Toxicologic Pathology

Volumn 56, Issue 4-5, 2005, Pages 313-319

  Gonzalez Navarro, Barbara ^a   Parada, Angel Casacó ^b   Alvarez, Pio ^c   Leon, Avelina ^a   Santana, Edilis ^a   Bada, Ana ^a   Figueredo, Rene ^b   Iznaga Escobar, Normando ^b   Perez, Rolando ^b  

^a Biomodels Unit   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^c CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

Author keywords

Cancer treatment; h R3; Monoclonal antibody; Osmium; Rhenium

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GLUCOHEPTONIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H R3; OSMIUM 188; RADIOISOTOPE; RHENIUM 188; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLOOD CHEMISTRY; BLOOD EXAMINATION; BLOOD SAMPLING; BODY WEIGHT; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; ISOTOPE LABELING; LATERAL BRAIN VENTRICLE; MALE; MOLECULAR STABILITY; NONHUMAN; RADIOISOTOPE DECAY; RAT; RECORDING; TOXICITY TESTING; WEIGHT GAIN;

EID: 14644424577     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etp.2004.07.004     Document Type: Article

References (26)

1. D.D. Bigner, M.T. Brown, and A.H. Friedman Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas phase I trial results J Clin Oncol 16 1998 2202 2212
2. A. Fernandez, R. Perez, and A. Macias Generación y caracterización primaria de anticuerpos monoclonales contra el receptor del factor de crecimiento epidérmico Interferón Biotecnol 6 1989 289 299
3. A. Fernandez, E. Spitzer, and R. Perez A new monoclonal antibody for detection of EGF-receptors in Western blots and paraffin-embedded tissue sections J Cell Biochem 49 1992 157 165
4. 188Re administered intracerebrally in rats Hum Exp Toxicol 19 2000 684 692
5. G.L. Griffiths, D.M. Goldenberg, and F.F. Knapp Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy labeling and animal biodistribution studies Cancer 51 1991 4594 4602
6. K. Hopkins, C. Chandler, and J. Bullimore A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates Radiother Oncol 34 1995 121 131
7. 90Y Moabs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma a model to estimate absorbed radiation dose Int J Radiat Oncol Biol Phys 40 1998 835 844
8. J. Ichikawa, and Y.H. Meltzer Amperozide, a novel antipychotic drug, inhibits the ability of d-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens J Neurochem 58 1992 2285 2291
9. N. Iznaga-Escobar, A. Morales, and G. Nuñez Micromethod for quantification of SH groups generated after reduction of monoclonal antibodies J Nucl Med Biol 23 1996 641 644
10. 188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors biodistribution, normal organ dosimetry, and toxicology Nucl Med Biol 25 1998 441 447
11. 99mTc-labeled anti-EGF-receptor antibody (ior egf/r3) in patients with tumor of epithelial origin. I. Biodistribution and dosimetry for radioimmunotherapy J Nucl Med 39 1998 15 23
12. S.J. Jubelirer A review of the treatment and survival rates of 138 patients with glioblastoma multiforme W Va Med J 92 1996 186 190
13. C. Mateo, E. Moreno, and K. Amour Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor recovery of antagonistic activity Immunotechnology 3 1997 71 81
14. E.W. Maynert Sedative and hypnotics I nonbarbiturates E.R. Dipalma Drill's pharmacology in medicine fourth ed 1971 McGraw-Hill Company New York 227 249
15. H. Modjtahedi, H. Mojtahed, and T. Hickish Phase I trial and tumour localization of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer Br J Cancer 73 1996 228 235
16. U. Murthy, A. Basu, and U. Rodeck Binding of antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide Arch Biochem Biophys 72 1987 77 89
17. 131I monoclonal antibody feasibility, pharmacokinetics and dosimetry Br J Cancer 67 1993 144 151
18. M.S. Patrick, and J.B. Justice Effect of general microdialysis-indhuced depletion on extracellular dopamine Anal Chem 68 1996 724 728
19. P. Riva, A. Arista, and C. Sturiale Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labeled anti-tenascin monoclonal antibody Int J Cancer 51 1992 7 13
20. P. Riva, A. Aristam, and V. Tisonm Intralesional radioimmunotherapy of malignant gliomas an effective treatment in recurrent tumors Cancer 73 1994 1076 1082
21. 90Y a fase I study Clin Cancer Res 5 1999 3275 3280
22. 131I radioconjugated antibodies for the locoregional, radioimmunotherapy of high-grade malignant Acta Oncol 38 1999 351 359
23. L. Snelling, C.T. Miyamoto, and H. Bender Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine 125 in adjuvant treatment of high-grade astrocitomas Hibridoma 14 1995 111 114
24. G. Stragliotto, F. Vega, and P. Stasiecki Multiple infusions of anti-epidermal grow factor receptor (EGFR) monoclonal antibody (EMD 55900) in patients with recurrent malignant gliomas Eur J Cancer 32A 1996 636 640
25. J.H. Thrall, J.E. Freitas, and D. Swanson Clinical comparison of cardiac blood pool visualization with technetium-99m red blood cells labeled in vivo and with technetium-99m human serum albumin J Nucl Med 19 1976 796 803
26. A. von Deimling, D.N. Louis, and K. von Ammon Association of epidermal grow factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme J Neurosurg 77 1992 295 301